Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treosulfan - Medac

Drug Profile

Treosulfan - Medac

Alternative Names: CB-2562; CB-40067; CCRIS 2781; Dihydroxybusulphan; HSDB-6963; NSC 39069; Ovastat; Trecondyv

Latest Information Update: 14 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medac
  • Developer Center for International Blood and Marrow Transplant Research; Fondazione San Raffaele; Medac; Medexus Pharmaceuticals
  • Class Antineoplastics; Butylene glycols; Mesylates; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Myelodysplastic syndromes; Ovarian cancer
  • Phase II Haematological malignancies; Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders; Myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Discontinued Malignant melanoma

Most Recent Events

  • 12 Jan 2023 Medexus pharmaceuticals announces intention to resubmit NDA to US FDA for Acute myeloid leukaemia and Myelodysplastic syndromes (in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation) in USA
  • 19 Sep 2022 Medac receives second notice of incomplete response from US FDA for treosulfan NDA resubmission
  • 09 Sep 2022 Medac plans a phase I pharmacokinetics trial (Combination therapy, In adults, In elderly) (IV) in October 2022 (NCT05534620)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top